Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Multicenter, randomized, open-label, parallel-group study to evaluate user satisfaction with and tolerability of the low-dose levonorgestrel (LNG) intrauterine delivery system (IUS) with 12 µg LNG/day initial in vitro release rate (LCS12) in comparison to a combined oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone (Yasmin®) in young nulliparous and parous women (18-29 years) over 18 months of use

    Summary
    EudraCT number
    		 2010-020181-21
    Trial protocol
    		 AT   BE   DE  
    Global end of trial date
    28 May 2014

    Results information
    Results version number
    		 v2
    This version publication date
    04 Sep 2016
    First version publication date
    10 May 2015
    Other versions
    		 v1 , v3
    Version creation reason
    • New data added to full data set
    • Correction of full data set
    Bayer sponsor contact information to be updated

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    BAY86-5028/13362
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT01254292
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Bayer AG
    Sponsor organisation address
    Kaiser-Wilhelm-Allee, Leverkusen, Germany, D-51368
    Public contact
    Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
    Scientific contact
    Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Interim
    Date of interim/final analysis
    08 Jan 2013
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    08 Jan 2013
    Global end of trial reached?
    Yes
    Global end of trial date
    28 May 2014
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this study was to evaluate user satisfaction in young nulliparous and parous women (18-29 years of age) using LCS12 compared with young nulliparous and parous women using a combined oral contraceptive (COC) over a period of 18 months.
    Protection of trial subjects
    The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    06 Jan 2011
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Austria: 173
    Country: Number of subjects enrolled
    Belgium: 101
    Country: Number of subjects enrolled
    Germany: 171
    Country: Number of subjects enrolled
    United States: 122
    Worldwide total number of subjects
    567
    EEA total number of subjects
    445
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    567
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 The study was conducted at 42 centers in Austria, Belgium, Germany, and the United States in healthy nulliparous and parous women.

    Pre-assignment
    Screening details
    		 A total of 644 subjects were screened of which 77 were screen failures and 567 were randomized, as follows: 282 subjects to LCS12 and 285 subjects to Yasmin. 279 subjects received treatment in LCS12 group and 281 in Yasmin group.

    Period 1
    Period 1 title
    Overall trial
    Is this the baseline period?
    		 No
    Allocation method
    Randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 LCS12 (Jaydess, BAY86-5028)
    Arm description
    		 Subjects received LCS12 for 18 months with optional extension to 36 months.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Levonorgestrel
    Investigational medicinal product code
    BAY86-5028
    Other name
    Skyla, Jaydess
    Pharmaceutical forms
    Intrauterine delivery system
    Routes of administration
    Intrauterine use
    Dosage and administration details
    Subjects received LCS12 for 18 months with optional extension to 36 months.

    Arm title
    		 EE30/DRSP (Yasmin, BAY86-5131)
    Arm description
    		 Subjects received COC tablet Yasmin containing 30 microgram ethinyl estradiol (EE) and 3 milligram (mg) drospirenone (DRSP) for 18 months per 19 cycles.
    Arm type
    		 Active comparator

    Investigational medicinal product name
    EE30/DRSP (Yasmin)
    Investigational medicinal product code
    BAY86-5131
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received COC tablet Yasmin containing 30 microgram EE and 3 mg DRSP for 18 months per 19 cycles.

    Number of subjects in period 1
    		LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Started
    282
    285
    Subjects Received Treatment
    279
    281
    Completed
    227
    204
    Not completed
    55
    81
         Consent withdrawn by subject
    20
    21
         Wish for pregnancy
    4
    6
         Protocol violation
    1
    2
         Pregnancy
    2
    6
         Adverse event
    25
    25
         Lost to follow-up
    3
    21
    Period 2
    Period 2 title
    Baseline period
    Is this the baseline period?
    		 Yes [1]
    Allocation method
    Randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    No

    Arm title
    		 LCS12 (Jaydess, BAY86-5028)
    Arm description
    		 Subjects received LCS12 for 18 months with optional extension to 36 months. Subjects who received treatment were included in baseline period.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Levonorgestrel
    Investigational medicinal product code
    BAY86-5028
    Other name
    Skyla, Jaydess
    Pharmaceutical forms
    Intrauterine delivery system
    Routes of administration
    Intrauterine use
    Dosage and administration details
    Subjects received LCS12 for 18 months with optional extension to 36 months.

    Arm title
    		 EE30/DRSP (Yasmin, BAY86-5131)
    Arm description
    		 Subjects received COC tablet Yasmin containing 30 microgram EE and 3 mg DRSP for 18 months per 19 cycles. Subjects who received treatment were included in baseline period.
    Arm type
    		 Active comparator

    Investigational medicinal product name
    EE30/DRSP (Yasmin)
    Investigational medicinal product code
    BAY86-5131
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received COC tablet Yasmin containing 30 microgram EE and 3 mg DRSP for 18 months per 19 cycles.

    Notes
    [1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.
    Justification: In overall trial, all subjects who were randomized were included and the baseline characteristics were provided only for subjects who were treated. Hence, the baseline period of treated subjects was created to publish the baseline characteristics data.
    Number of subjects in period 2
    		LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Started
    279
    281
    Completed
    279
    281

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups [1]
    Reporting group title
    LCS12 (Jaydess, BAY86-5028)
    Reporting group description
    		 Subjects received LCS12 for 18 months with optional extension to 36 months. Subjects who received treatment were included in baseline period.

    Reporting group title
    EE30/DRSP (Yasmin, BAY86-5131)
    Reporting group description
    		 Subjects received COC tablet Yasmin containing 30 microgram EE and 3 mg DRSP for 18 months per 19 cycles. Subjects who received treatment were included in baseline period.

    Notes
    [1] - The number of subjects reported to be in the baseline period is not equal to the worldwide number of subjects enrolled in the trial. It is expected that these numbers will be the same.
    Justification: Not all randomized subjects were treated with study drugs. Hence, the worldwide number enrolled in the trial, which is the same as the number randomized, differs from the number of subjects reported in the baseline period.
    Reporting group values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131) Total
    Number of subjects
    		 279 281 560
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    		 279 281 560
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    		 23.7 ( 3 ) 23.9 ( 3 ) -
    Gender categorical
    Units: Subjects
        Female
    		 279 281 560
    Number of births
    Units: Subjects
        Zero
    		 216 206 422
        One
    		 39 49 88
        Two
    		 19 24 43
        Three
    		 4 2 6
        Four
    		 1 0 1

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    LCS12 (Jaydess, BAY86-5028)
    Reporting group description
    		 Subjects received LCS12 for 18 months with optional extension to 36 months.

    Reporting group title
    EE30/DRSP (Yasmin, BAY86-5131)
    Reporting group description
    		 Subjects received COC tablet Yasmin containing 30 microgram ethinyl estradiol (EE) and 3 milligram (mg) drospirenone (DRSP) for 18 months per 19 cycles.
    Reporting group title
    LCS12 (Jaydess, BAY86-5028)
    Reporting group description
    		 Subjects received LCS12 for 18 months with optional extension to 36 months. Subjects who received treatment were included in baseline period.

    Reporting group title
    EE30/DRSP (Yasmin, BAY86-5131)
    Reporting group description
    		 Subjects received COC tablet Yasmin containing 30 microgram EE and 3 mg DRSP for 18 months per 19 cycles. Subjects who received treatment were included in baseline period.

    Subject analysis set title
    Full analysis set (FAS)
    Subject analysis set type
    		 Full analysis
    Subject analysis set description
    The FAS included all randomized subjects who received treatment (i.e., who took at least one tablet of Yasmin or who had a successful or unsuccessful insertion attempt of LCS12). All subjects in the FAS were analyzed according to the treatment they actually received. The FAS population comprised of 560 subjects, including 279 subjects randomized to LCS12 and 281 subjects randomized to Yasmin.

    Primary: Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF)

    		 Close Top of page
    End point title
    		 Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF) [1]
    End point description
    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied. The overall satisfaction rate is the percentage of subjects selecting “1. Very satisfied” or “2. Satisfied” for the above question.
    End point type
    Primary
    End point timeframe
    At 18 months
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Statistical analysis was not performed since descriptive statistical analysis was only planned for this endpoint.
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    274 [2]
    260 [3]
    Units: percentage of subjects
        number (confidence interval 95%)
    82.1 (77.1 to 86.5)
    81.9 (76.7 to 86.4)
    Notes
    [2] - FAS (only subjects with at least one assessment of the overall satisfaction rating)
    [3] - FAS (only subjects with at least one assessment of the overall satisfaction rating)
    No statistical analyses for this end point

    Secondary: Overall Satisfaction Rating by the 5-Point Likert Item at 6 Months

    		 Close Top of page
    End point title
    		 Overall Satisfaction Rating by the 5-Point Likert Item at 6 Months
    End point description
    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting “1. Very satisfied” or “2. Satisfied” for the above question.
    End point type
    Secondary
    End point timeframe
    At 6 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    273 [4]
    260 [5]
    Units: percentage of subjects
    number (not applicable)
        Very Satisfied
    60.4
    48.1
        Satisfied
    27.5
    35.8
        Neither satisfied nor dissatisfied
    7.3
    9.6
        Dissatisfied
    1.8
    6.2
        Very Dissatisfied
    2.9
    0.4
    Notes
    [4] - FAS (only subjects with an assessment of overall satisfaction rating at 6 months)
    [5] - FAS (only subjects with an assessment of overall satisfaction rating at 6 months)
    No statistical analyses for this end point

    Secondary: Overall Satisfaction Rating by the 5-Point Likert Item at 12 Months

    		 Close Top of page
    End point title
    		 Overall Satisfaction Rating by the 5-Point Likert Item at 12 Months
    End point description
    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting “1. Very satisfied” or “2. Satisfied” for the above question.
    End point type
    Secondary
    End point timeframe
    At 12 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    253 [6]
    238 [7]
    Units: percentage of subjects
    number (not applicable)
        Very Satisfied
    66.8
    45
        Satisfied
    22.9
    44.1
        Neither satisfied nor dissatisfied
    5.9
    5.9
        Dissatisfied
    4.3
    3.8
        Very Dissatisfied
    0
    1.3
    Notes
    [6] - FAS (only subjects with an assessment of overall satisfaction rating at 12 months)
    [7] - FAS (only subjects with an assessment of overall satisfaction rating at 12 months)
    No statistical analyses for this end point

    Secondary: Overall Satisfaction Rating by the 5-Point Likert Item at 18 Months

    		 Close Top of page
    End point title
    		 Overall Satisfaction Rating by the 5-Point Likert Item at 18 Months
    End point description
    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied. The overall satisfaction rate was to be the percentage of subjects selecting “1. Very satisfied” or “2. Satisfied” for the above question.
    End point type
    Secondary
    End point timeframe
    At 18 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    235 [8]
    217 [9]
    Units: percentage of subjects
    number (not applicable)
        Very Satisfied
    64.3
    52.5
        Satisfied
    25.1
    37.8
        Neither satisfied nor dissatisfied
    6.4
    6.9
        Dissatisfied
    3
    2.8
        Very Dissatisfied
    1.3
    0
    Notes
    [8] - FAS (only subjects with an assessment of overall satisfaction rating at 18 months)
    [9] - FAS (only subjects with an assessment of overall satisfaction rating at 18 months)
    No statistical analyses for this end point

    Secondary: Overall Satisfaction Rating by the 5-Point Likert Item at End of Study (EOS)

    		 Close Top of page
    End point title
    		 Overall Satisfaction Rating by the 5-Point Likert Item at End of Study (EOS)
    End point description
    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied The overall satisfaction rate was to be the percentage of subjects selecting “1. Very satisfied” or “2. Satisfied” for the above question.
    End point type
    Secondary
    End point timeframe
    At 18 months/EOS
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    268 [10]
    251 [11]
    Units: percentage of subjects
    number (not applicable)
        Very Satisfied
    58.6
    46.6
        Satisfied
    23.5
    35.1
        Neither satisfied nor dissatisfied
    8.6
    9.6
        Dissatisfied
    5.6
    7.6
        Very Dissatisfied
    3.7
    1.2
    Notes
    [10] - FAS (only subjects with an assessment of overall satisfaction rating at 18 months/EOS)
    [11] - FAS (only subjects with an assessment of overall satisfaction rating at 18 months/EOS)
    No statistical analyses for this end point

    Secondary: Overall Satisfaction Rate at 6 Months (LOCF)

    		 Close Top of page
    End point title
    		 Overall Satisfaction Rate at 6 Months (LOCF)
    End point description
    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied. The overall satisfaction rate was to be the percentage of subjects selecting “1. Very satisfied” or “2. Satisfied” for the above question.
    End point type
    Secondary
    End point timeframe
    At 6 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    273 [12]
    260 [13]
    Units: percentage of subjects
        number (not applicable)
    87.9
    83.8
    Notes
    [12] - FAS (only subjects with an assessment of overall satisfaction rating at 6 months or before)
    [13] - FAS (only subjects with an assessment of overall satisfaction rating at 6 months or before)
    No statistical analyses for this end point

    Secondary: Overall Satisfaction Rate at 12 Months (LOCF)

    		 Close Top of page
    End point title
    		 Overall Satisfaction Rate at 12 Months (LOCF)
    End point description
    Satisfaction was to be assessed by the subject based on a 5-point Likert item, using the following question: How satisfied are you with the birth control method used during the study? 1. Very satisfied 2. Satisfied 3. Neither satisfied nor dissatisfied 4. Dissatisfied 5. Very dissatisfied. The overall satisfaction rate was to be the percentage of subjects selecting “1. Very satisfied” or “2. Satisfied” for the above question.
    End point type
    Secondary
    End point timeframe
    At 12 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    274 [14]
    260 [15]
    Units: percentage of subjects
        number (not applicable)
    84.3
    83.8
    Notes
    [14] - FAS (only subjects with an assessment of overall satisfaction rating at 12 months)
    [15] - FAS (only subjects with an assessment of overall satisfaction rating at 12 months)
    No statistical analyses for this end point

    Secondary: User Satisfaction – Acceptability of the Administration of Study Treatment

    		 Close Top of page
    End point title
    		 User Satisfaction – Acceptability of the Administration of Study Treatment
    End point description
    The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without inconvenience/discomfort (I/D), acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D.
    End point type
    Secondary
    End point timeframe
    At 18 months/EOS
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    263 [16]
    250 [17]
    Units: subjects
        Acceptable without I/D
    153
    186
        Acceptable with some I/D
    87
    46
        Not acceptable with moderate I/D
    11
    15
        Not acceptable with extreme I/D
    12
    3
    Notes
    [16] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    [17] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    No statistical analyses for this end point

    Secondary: User Satisfaction – Choices Upon Completion of the Study

    		 Close Top of page
    End point title
    		 User Satisfaction – Choices Upon Completion of the Study
    End point description
    End point type
    Secondary
    End point timeframe
    At 18 months/EOS
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    263 [18]
    248 [19]
    Units: subjects
        Continue with study treatment
    174
    122
        Use a different hormonal contraceptive
    34
    51
        Use a different contraceptive method
    17
    27
        Discontinue use of all types of contraceptive
    6
    14
        No need for contraceptive at this time
    5
    12
        Undecided
    27
    22
    Notes
    [18] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    [19] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    No statistical analyses for this end point

    Secondary: User Satisfaction – Amount of Menstrual Bleeding

    		 Close Top of page
    End point title
    		 User Satisfaction – Amount of Menstrual Bleeding
    End point description
    End point type
    Secondary
    End point timeframe
    At 18 months/EOS
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    260 [20]
    250 [21]
    Units: subjects
        Decreased
    80
    35
        Not Changed
    163
    207
        Increased
    17
    8
    Notes
    [20] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    [21] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    No statistical analyses for this end point

    Secondary: User Satisfaction – Satisfaction With Menstrual Bleeding Pattern

    		 Close Top of page
    End point title
    		 User Satisfaction – Satisfaction With Menstrual Bleeding Pattern
    End point description
    End point type
    Secondary
    End point timeframe
    At 18 months/EOS
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    263 [22]
    250 [23]
    Units: subjects
        Very satisfied
    101
    91
        Somewhat satisfied
    65
    84
        Neither satisfied nor dissatisfied
    48
    68
        Dissatisfied
    19
    4
        Very dissatisfied
    10
    1
        Not applicable
    20
    2
    Notes
    [22] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    [23] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    No statistical analyses for this end point

    Secondary: User Satisfaction – Frequency of Experiencing Unexpected Bleeding

    		 Close Top of page
    End point title
    		 User Satisfaction – Frequency of Experiencing Unexpected Bleeding
    End point description
    End point type
    Secondary
    End point timeframe
    At 18 months/EOS
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    263 [24]
    250 [25]
    Units: subjects
        Never
    145
    219
        Seldom
    92
    25
        Often
    17
    5
        Very Often
    9
    1
    Notes
    [24] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    [25] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    No statistical analyses for this end point

    Secondary: User Satisfaction – Satisfaction With Menstrual Bleeding Absence

    		 Close Top of page
    End point title
    		 User Satisfaction – Satisfaction With Menstrual Bleeding Absence
    End point description
    End point type
    Secondary
    End point timeframe
    At 18 months/EOS
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    130 [26]
    14 [27]
    Units: subjects
        Very satisfied
    96
    6
        Somewhat satisfied
    18
    0
        Neither satisfied nor dissatisfied
    14
    8
        Dissatisfied
    1
    0
        Very dissatisfied
    1
    0
    Notes
    [26] - FAS (only subjects with an assessment of this questions of the user satisfaction questionnaire)
    [27] - FAS (only subjects with an assessment of this questions of the user satisfaction questionnaire)
    No statistical analyses for this end point

    Secondary: User Satisfaction – Comparison of Menstrual Pain Intensity Between Now and Before Treatment

    		 Close Top of page
    End point title
    		 User Satisfaction – Comparison of Menstrual Pain Intensity Between Now and Before Treatment
    End point description
    End point type
    Secondary
    End point timeframe
    At 18 months/EOS
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    259 [28]
    247 [29]
    Units: subjects
        Decreased
    118
    61
        Not changed
    102
    169
        Increased
    39
    17
    Notes
    [28] - FAS (only subjects with an assessment of this questions of the user satisfaction questionnaire)
    [29] - FAS (only subjects with an assessment of this questions of the user satisfaction questionnaire)
    No statistical analyses for this end point

    Secondary: User Satisfaction – Rating of Usual Menstrual Pain Intensity

    		 Close Top of page
    End point title
    		 User Satisfaction – Rating of Usual Menstrual Pain Intensity
    End point description
    End point type
    Secondary
    End point timeframe
    At 18 months/EOS
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    261 [30]
    249 [31]
    Units: subjects
        None
    124
    82
        Mild
    78
    92
        Moderate
    43
    67
        Severe
    16
    8
    Notes
    [30] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    [31] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    No statistical analyses for this end point

    Secondary: EVAPIL-R Scores at Screening - Composite Score

    		 Close Top of page
    End point title
    		 EVAPIL-R Scores at Screening - Composite Score
    End point description
    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.
    End point type
    Secondary
    End point timeframe
    At screening
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    273 [32]
    275 [33]
    Units: scores on a scale
        arithmetic mean (standard deviation)
    0.9386 ( 0.8036 )
    0.8846 ( 0.8231 )
    Notes
    [32] - FAS (subjects with an assessment of the EVAPIL questionnaire where this score could be calculated)
    [33] - FAS (subjects with an assessment of the EVAPIL questionnaire where this score could be calculated)
    No statistical analyses for this end point

    Secondary: EVAPIL-R Scores at Screening - Bother Score

    		 Close Top of page
    End point title
    		 EVAPIL-R Scores at Screening - Bother Score
    End point description
    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.
    End point type
    Secondary
    End point timeframe
    At screening
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    273 [34]
    276 [35]
    Units: scores on a scale
        arithmetic mean (standard deviation)
    0.5569 ( 0.4451 )
    0.5188 ( 0.4406 )
    Notes
    [34] - FAS (subjects with an assessment of the EVAPIL questionnaire where bother score could be calculated)
    [35] - FAS (subjects with an assessment of the EVAPIL questionnaire where bother score could be calculated)
    No statistical analyses for this end point

    Secondary: EVAPIL-R Scores at 6 Months

    		 Close Top of page
    End point title
    		 EVAPIL-R Scores at 6 Months
    End point description
    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability.
    End point type
    Secondary
    End point timeframe
    At 6 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    252 [36]
    243 [37]
    Units: scores on a scale
    arithmetic mean (standard deviation)
        Composite score
    1.3187 ( 0.9888 )
    1.1537 ( 0.9947 )
        Bother score
    0.7364 ( 0.494 )
    0.655 ( 0.5148 )
    Notes
    [36] - FAS (subjects with an assessment of the EVAPIL questionnaire where this scores could be calculated)
    [37] - FAS (subjects with an assessment of the EVAPIL questionnaire where this scores could be calculated)
    No statistical analyses for this end point

    Secondary: EVAPIL-R Scores at 12 Months - Composite Score

    		 Close Top of page
    End point title
    		 EVAPIL-R Scores at 12 Months - Composite Score
    End point description
    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. FAS included only subjects with an assessment of the EVAPIL questionnaire at 12 months where the composite score could be calculated.
    End point type
    Secondary
    End point timeframe
    At 12 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    229 [38]
    218 [39]
    Units: scores on a scale
        arithmetic mean (standard deviation)
    1.4022 ( 1.0126 )
    1.0535 ( 0.8698 )
    Notes
    [38] - FAS (subjects with an assessment of the EVAPIL questionnaire where this score could be calculated)
    [39] - FAS (subjects with an assessment of the EVAPIL questionnaire where this score could be calculated)
    No statistical analyses for this end point

    Secondary: EVAPIL-R Scores at 12 Months - Bother Score

    		 Close Top of page
    End point title
    		 EVAPIL-R Scores at 12 Months - Bother Score
    End point description
    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. FAS included only subjects with an assessment of the EVAPIL questionnaire at 12 months where the bother score could be calculated.
    End point type
    Secondary
    End point timeframe
    At 12 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    233
    218
    Units: scores on a scale
        arithmetic mean (standard deviation)
    0.7789 ( 0.512 )
    0.6015 ( 0.4663 )
    No statistical analyses for this end point

    Secondary: EVAPIL-R Scores at 18 Months/EOS

    		 Close Top of page
    End point title
    		 EVAPIL-R Scores at 18 Months/EOS
    End point description
    The EVAPIL-R scale is a self-questionnaire aimed to assess tolerability of oral contraceptives. A composite score was derived from 16 items and the ratings for presence/absence (rated as 1/0), frequency (rated with values from 0 to 2), intensity (rated from 1 to 3) and bother (rated from 1 to 4) for each item. To calculate the composite score, the bother rating of each item was multiplied by an item- specific multiplier and a weight. Range is 0-12, with higher values indicating more severe symptoms/less tolerability. FAS included only subjects with an assessment of the EVAPIL questionnaire at 18 months/EOS where the scores could be calculated.
    End point type
    Secondary
    End point timeframe
    At 18 months/EOS
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    260 [40]
    250 [41]
    Units: scores on a scale
    arithmetic mean (standard deviation)
        Composite score
    1.4804 ( 1.1926 )
    1.0246 ( 0.9546 )
        Bother score
    0.8113 ( 0.5765 )
    0.5908 ( 0.4836 )
    Notes
    [40] - FAS (subjects with an assessment of the EVAPIL questionnaire where this score could be calculated)
    [41] - FAS (subjects with an assessment of the EVAPIL questionnaire where this score could be calculated)
    No statistical analyses for this end point

    Secondary: Drop-out Rate

    		 Close Top of page
    End point title
    		 Drop-out Rate
    End point description
    The drop-out rate was the amount of subjects that could not complete the study for various reasons. Overall discontinuation rates were analyzed by Kaplan-Meier analyses and presented as cumulative half-yearly drop-out rates.
    End point type
    Secondary
    End point timeframe
    At 6, 12 and 18 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    279 [42]
    281 [43]
    Units: percentage of subjects
    number (not applicable)
        at 6 months
    7.53
    11.39
        at 12 months
    13.26
    21.71
        at 18 months
    18.64
    27.4
    Notes
    [42] - FAS
    [43] - FAS
    No statistical analyses for this end point

    Secondary: Pearl Index (PI)

    		 Close Top of page
    End point title
    		 Pearl Index (PI)
    End point description
    The Pearl Index was defined as the number of pregnancies per 100 woman years (WYs). Given the assumption that the number of pregnancies follows a Poisson distribution, the Pearl Index thus is the mean of this distribution.
    End point type
    Secondary
    End point timeframe
    Up to 18 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    279 [44]
    281 [45]
    Units: pregnancies per 100 women years
        arithmetic mean (confidence interval 95%)
    0.57 (0.07 to 2.05)
    1.82 (0.67 to 3.97)
    Notes
    [44] - FAS
    [45] - FAS
    No statistical analyses for this end point

    Secondary: Compliance Rate for Yasmin Pill Intake

    		 Close Top of page
    End point title
    		 Compliance Rate for Yasmin Pill Intake
    End point description
    End point type
    Secondary
    End point timeframe
    Up to 18 months
    End point values
    		 EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    281 [46]
    Units: percentage of subjects
    number (not applicable)
        Missing
    2.8
        Compliance <=75%
    2.1
        Compliance >75%
    95
    Notes
    [46] - FAS
    No statistical analyses for this end point

    Secondary: User Satisfaction – Acceptability of the Administration of Study Treatment

    		 Close Top of page
    End point title
    		 User Satisfaction – Acceptability of the Administration of Study Treatment
    End point description
    The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D.
    End point type
    Secondary
    End point timeframe
    At 6 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    256 [47]
    244 [48]
    Units: subjects
        Acceptable without I/D
    163
    192
        Acceptable with some I/D
    87
    48
        Not acceptable with moderate I/D
    4
    4
        Not acceptable with extreme I/D
    2
    0
    Notes
    [47] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    [48] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    No statistical analyses for this end point

    Secondary: User Satisfaction – Acceptability of the Administration of Study Treatment

    		 Close Top of page
    End point title
    		 User Satisfaction – Acceptability of the Administration of Study Treatment
    End point description
    The degree of user satisfaction was assessed at the end-of-study visit using an eight item questionnaire. One of the items assessed was acceptability of study treatment which was categorized into the following: acceptable without I/D, acceptable with some I/D, not acceptable with moderate I/D, and not acceptable with extreme I/D.
    End point type
    Secondary
    End point timeframe
    At 12 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Number of subjects analysed
    237 [49]
    220 [50]
    Units: subjects
        Acceptable without I/D
    152
    185
        Acceptable with some I/D
    74
    33
        Not acceptable with moderate I/D
    9
    2
        Not acceptable with extreme I/D
    1
    0
    Notes
    [49] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    [50] - FAS (only subjects with an assessment of these questions of the user satisfaction questionnaire)
    No statistical analyses for this end point

    Other pre-specified: Number of Subjects With Partial or Total Expulsion

    		 Close Top of page
    End point title
    		 Number of Subjects With Partial or Total Expulsion
    End point description
    Total expulsion is confirmed if the IUS is observed in the vagina, the IUS is not shown in the uterine cavity by ultrasound, and / or the subject confirms that the system was expelled. Partial expulsion is diagnosed if the IUS can be partially seen in the vagina or is displaced in the cervical canal.
    End point type
    Other pre-specified
    End point timeframe
    Up to 18 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028)
    Number of subjects analysed
    279 [51]
    Units: subjects
        Partial expulsion
    0
        Total expulsion
    0
    Notes
    [51] - FAS
    No statistical analyses for this end point

    Other pre-specified: Investigator's Evaluation of Successful IUS Insertion Procedure

    		 Close Top of page
    End point title
    		 Investigator's Evaluation of Successful IUS Insertion Procedure
    End point description
    End point type
    Other pre-specified
    End point timeframe
    Up to 18 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028)
    Number of subjects analysed
    279 [52]
    Units: subjects
        Easy
    247
        Slightly difficult
    31
        Very difficult
    1
    Notes
    [52] - FAS
    No statistical analyses for this end point

    Other pre-specified: Subjects’ Evaluation of Pain During Successful IUS Insertion Procedure

    		 Close Top of page
    End point title
    		 Subjects’ Evaluation of Pain During Successful IUS Insertion Procedure
    End point description
    End point type
    Other pre-specified
    End point timeframe
    Up to 18 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028)
    Number of subjects analysed
    279 [53]
    Units: subjects
        None
    49
        Mild
    125
        Moderate
    80
        Severe
    25
    Notes
    [53] - FAS
    No statistical analyses for this end point

    Other pre-specified: Investigator's Evaluation of IUS Removal Procedure

    		 Close Top of page
    End point title
    		 Investigator's Evaluation of IUS Removal Procedure
    End point description
    End point type
    Other pre-specified
    End point timeframe
    Up to 18 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028)
    Number of subjects analysed
    76 [54]
    Units: subjects
        Missing
    2
        Easy
    70
        Slightly difficult
    3
        Very difficult
    1
    Notes
    [54] - FAS (only subjects in the LCS12 arm with documented removal of the IUS)
    No statistical analyses for this end point

    Other pre-specified: Subjects’ Evaluation of Pain During IUS Removal Procedure

    		 Close Top of page
    End point title
    		 Subjects’ Evaluation of Pain During IUS Removal Procedure
    End point description
    End point type
    Other pre-specified
    End point timeframe
    Up to 18 months
    End point values
    		 LCS12 (Jaydess, BAY86-5028)
    Number of subjects analysed
    76 [55]
    Units: subjects
        Missing
    3
        None
    43
        Mild
    24
        Moderate
    5
        Severe
    1
    Notes
    [55] - FAS (only subjects in the LCS12 arm with documented removal of the IUS)
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From start of treatment until 18 months/EOS visit
    Assessment type
    		 Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    15.1
    Reporting groups
    Reporting group title
    LCS12 (Jaydess, BAY86-5028)
    Reporting group description
    		 Subjects received LCS12 for 18 months with optional extension to 36 months.

    Reporting group title
    EE30/DRSP (Yasmin, BAY86-5131)
    Reporting group description
    		 Subjects received COC tablet Yasmin containing 30 microgram EE and 3 mg DRSP for 18 months per 19 cycles.

    Serious adverse events
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    13 / 279 (4.66%)
    6 / 281 (2.14%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Cervix carcinoma stage 0
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Malignant melanoma
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Incisional hernia
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Laceration
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ligament rupture
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Muscle injury
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    Abortion spontaneous
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ectopic pregnancy
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Impaired healing
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Colitis ulcerative
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Femoral hernia
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Cervical dysplasia
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ovarian cyst
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endocrine disorders
    Basedow's disease
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Exostosis
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nose deformity
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Appendicitis
         subjects affected / exposed
    1 / 279 (0.36%)
    2 / 281 (0.71%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infectious mononucleosis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    		 LCS12 (Jaydess, BAY86-5028) EE30/DRSP (Yasmin, BAY86-5131)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    209 / 279 (74.91%)
    167 / 281 (59.43%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Anogenital warts
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Breast adenoma
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Uterine leiomyoma
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Fibroadenoma of breast
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Vulvovaginal human papilloma virus infection
         subjects affected / exposed
    0 / 279 (0.00%)
    2 / 281 (0.71%)
         occurrences all number
    0
    2
    Vascular disorders
    Haematoma
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Hot flush
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Surgical and medical procedures
    Abscess drainage
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Endodontic procedure
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Mole excision
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    2
    Mammoplasty
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Tooth extraction
         subjects affected / exposed
    2 / 279 (0.72%)
    1 / 281 (0.36%)
         occurrences all number
    3
    1
    Wisdom teeth removal
         subjects affected / exposed
    4 / 279 (1.43%)
    1 / 281 (0.36%)
         occurrences all number
    4
    1
    Umbilical hernia repair
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    General disorders and administration site conditions
    Chest pain
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Chronic fatigue syndrome
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Cyst
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Device dislocation
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Discomfort
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Fatigue
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Influenza like illness
         subjects affected / exposed
    0 / 279 (0.00%)
    2 / 281 (0.71%)
         occurrences all number
    0
    2
    Irritability
         subjects affected / exposed
    3 / 279 (1.08%)
    1 / 281 (0.36%)
         occurrences all number
    3
    1
    Medical device pain
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    4
    0
    Malaise
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Oedema peripheral
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Pain
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Pyrexia
         subjects affected / exposed
    3 / 279 (1.08%)
    2 / 281 (0.71%)
         occurrences all number
    3
    2
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Hypersensitivity
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Seasonal allergy
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Reproductive system and breast disorders
    Adnexa uteri cyst
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Adnexa uteri pain
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Amenorrhoea
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Bartholin's cyst
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Breast atrophy
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Breast discomfort
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Breast discharge
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    3
    0
    Breast disorder
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Breast fibrosis
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Breast pain
         subjects affected / exposed
    3 / 279 (1.08%)
    1 / 281 (0.36%)
         occurrences all number
    3
    1
    Breast swelling
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Breast tenderness
         subjects affected / exposed
    3 / 279 (1.08%)
    2 / 281 (0.71%)
         occurrences all number
    3
    2
    Cervix haemorrhage uterine
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Cervical dysplasia
         subjects affected / exposed
    25 / 279 (8.96%)
    16 / 281 (5.69%)
         occurrences all number
    29
    17
    Coital bleeding
         subjects affected / exposed
    3 / 279 (1.08%)
    1 / 281 (0.36%)
         occurrences all number
    3
    1
    Dyspareunia
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Dysmenorrhoea
         subjects affected / exposed
    45 / 279 (16.13%)
    26 / 281 (9.25%)
         occurrences all number
    71
    73
    Ectropion of cervix
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Endometrial hypertrophy
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Galactorrhoea
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Genital discharge
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Haemorrhagic ovarian cyst
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Genital haemorrhage
         subjects affected / exposed
    6 / 279 (2.15%)
    0 / 281 (0.00%)
         occurrences all number
    8
    0
    Menometrorrhagia
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Menorrhagia
         subjects affected / exposed
    5 / 279 (1.79%)
    5 / 281 (1.78%)
         occurrences all number
    5
    5
    Metrorrhagia
         subjects affected / exposed
    9 / 279 (3.23%)
    1 / 281 (0.36%)
         occurrences all number
    12
    1
    Menstruation irregular
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Nipple pain
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Ovarian cyst
         subjects affected / exposed
    19 / 279 (6.81%)
    0 / 281 (0.00%)
         occurrences all number
    20
    0
    Oligomenorrhoea
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Ovarian cyst ruptured
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Ovulation pain
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Pelvic discomfort
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Pelvic pain
         subjects affected / exposed
    12 / 279 (4.30%)
    0 / 281 (0.00%)
         occurrences all number
    13
    0
    Uterine haemorrhage
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Uterine pain
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Vaginal discharge
         subjects affected / exposed
    6 / 279 (2.15%)
    0 / 281 (0.00%)
         occurrences all number
    6
    0
    Vaginal haemorrhage
         subjects affected / exposed
    6 / 279 (2.15%)
    0 / 281 (0.00%)
         occurrences all number
    6
    0
    Vulval haematoma
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Vaginal odour
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Vulvovaginal dryness
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Vulvovaginal pruritus
         subjects affected / exposed
    2 / 279 (0.72%)
    1 / 281 (0.36%)
         occurrences all number
    2
    2
    Vulvovaginal pain
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    2
    1
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    1 / 279 (0.36%)
    3 / 281 (1.07%)
         occurrences all number
    1
    3
    Dyspnoea
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Oropharyngeal pain
         subjects affected / exposed
    5 / 279 (1.79%)
    2 / 281 (0.71%)
         occurrences all number
    6
    2
    Rhinitis allergic
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Psychiatric disorders
    Affective disorder
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Adjustment disorder
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Anxiety
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Depressed mood
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Attention deficit/hyperactivity disorder
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Depression
         subjects affected / exposed
    1 / 279 (0.36%)
    4 / 281 (1.42%)
         occurrences all number
    1
    4
    Insomnia
         subjects affected / exposed
    0 / 279 (0.00%)
    4 / 281 (1.42%)
         occurrences all number
    0
    5
    Libido decreased
         subjects affected / exposed
    1 / 279 (0.36%)
    3 / 281 (1.07%)
         occurrences all number
    1
    3
    Loss of libido
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Mood swings
         subjects affected / exposed
    0 / 279 (0.00%)
    2 / 281 (0.71%)
         occurrences all number
    0
    2
    Mood altered
         subjects affected / exposed
    1 / 279 (0.36%)
    3 / 281 (1.07%)
         occurrences all number
    1
    3
    Nervousness
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Sleep disorder
         subjects affected / exposed
    0 / 279 (0.00%)
    2 / 281 (0.71%)
         occurrences all number
    0
    2
    Stress
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Investigations
    Blood pressure decreased
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Chlamydia test positive
         subjects affected / exposed
    1 / 279 (0.36%)
    2 / 281 (0.71%)
         occurrences all number
    1
    2
    Body temperature increased
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    2
    Gardnerella test positive
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Helicobacter test positive
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Human papilloma virus test positive
         subjects affected / exposed
    4 / 279 (1.43%)
    3 / 281 (1.07%)
         occurrences all number
    4
    3
    Liver function test abnormal
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Smear cervix abnormal
         subjects affected / exposed
    5 / 279 (1.79%)
    0 / 281 (0.00%)
         occurrences all number
    6
    0
    Weight decreased
         subjects affected / exposed
    1 / 279 (0.36%)
    3 / 281 (1.07%)
         occurrences all number
    1
    3
    Weight increased
         subjects affected / exposed
    6 / 279 (2.15%)
    8 / 281 (2.85%)
         occurrences all number
    6
    8
    Injury, poisoning and procedural complications
    Accident
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    2
    Animal bite
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Arthropod bite
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Epicondylitis
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Contusion
         subjects affected / exposed
    0 / 279 (0.00%)
    3 / 281 (1.07%)
         occurrences all number
    0
    3
    Humerus fracture
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Joint dislocation
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Laceration
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Ligament rupture
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Ligament sprain
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Limb injury
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Muscle strain
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Post procedural complication
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Post procedural discomfort
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Post-traumatic neck syndrome
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Post-traumatic pain
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    2
    Procedural pain
         subjects affected / exposed
    10 / 279 (3.58%)
    1 / 281 (0.36%)
         occurrences all number
    10
    2
    Procedural nausea
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Road traffic accident
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Thermal burn
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Stress fracture
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Tooth fracture
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Cardiac disorders
    Cardiovascular disorder
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Palpitations
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Nervous system disorders
    Aphonia psychogenic
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Dizziness
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Epilepsy
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Headache
         subjects affected / exposed
    21 / 279 (7.53%)
    33 / 281 (11.74%)
         occurrences all number
    72
    56
    Hypertonia
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Migraine
         subjects affected / exposed
    2 / 279 (0.72%)
    5 / 281 (1.78%)
         occurrences all number
    2
    11
    Neuritis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Neuropathy peripheral
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Presyncope
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Sciatica
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Syncope
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Iron deficiency anaemia
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Lymphadenopathy
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    3 / 279 (1.08%)
    0 / 281 (0.00%)
         occurrences all number
    3
    0
    Eye disorders
    Uveitis
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Gastrointestinal disorders
    Abdominal discomfort
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    2
    Abdominal distension
         subjects affected / exposed
    2 / 279 (0.72%)
    1 / 281 (0.36%)
         occurrences all number
    2
    1
    Abdominal pain
         subjects affected / exposed
    21 / 279 (7.53%)
    4 / 281 (1.42%)
         occurrences all number
    31
    5
    Abdominal pain upper
         subjects affected / exposed
    3 / 279 (1.08%)
    6 / 281 (2.14%)
         occurrences all number
    3
    6
    Abdominal pain lower
         subjects affected / exposed
    9 / 279 (3.23%)
    5 / 281 (1.78%)
         occurrences all number
    16
    5
    Colitis ulcerative
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Diarrhoea
         subjects affected / exposed
    1 / 279 (0.36%)
    9 / 281 (3.20%)
         occurrences all number
    1
    11
    Constipation
         subjects affected / exposed
    0 / 279 (0.00%)
    4 / 281 (1.42%)
         occurrences all number
    0
    4
    Dyspepsia
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Gastric mucosa erythema
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Gastrooesophageal reflux disease
         subjects affected / exposed
    3 / 279 (1.08%)
    3 / 281 (1.07%)
         occurrences all number
    3
    3
    Gastritis
         subjects affected / exposed
    4 / 279 (1.43%)
    4 / 281 (1.42%)
         occurrences all number
    4
    5
    Haemorrhoids
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Hypoaesthesia oral
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Hiatus hernia
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Nausea
         subjects affected / exposed
    9 / 279 (3.23%)
    14 / 281 (4.98%)
         occurrences all number
    16
    16
    Proctitis
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Toothache
         subjects affected / exposed
    3 / 279 (1.08%)
    2 / 281 (0.71%)
         occurrences all number
    4
    2
    Rectal haemorrhage
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Vomiting
         subjects affected / exposed
    3 / 279 (1.08%)
    8 / 281 (2.85%)
         occurrences all number
    3
    9
    Hepatobiliary disorders
    Cholelithiasis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Skin and subcutaneous tissue disorders
    Acne
         subjects affected / exposed
    30 / 279 (10.75%)
    5 / 281 (1.78%)
         occurrences all number
    35
    5
    Alopecia
         subjects affected / exposed
    2 / 279 (0.72%)
    1 / 281 (0.36%)
         occurrences all number
    2
    1
    Dermatitis
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Dermatitis contact
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Dermatitis acneiform
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Eczema
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    2
    1
    Hidradenitis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Hyperhidrosis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Lichen sclerosus
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Photosensitivity reaction
         subjects affected / exposed
    0 / 279 (0.00%)
    2 / 281 (0.71%)
         occurrences all number
    0
    2
    Psoriasis
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Rash
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Seborrhoea
         subjects affected / exposed
    2 / 279 (0.72%)
    1 / 281 (0.36%)
         occurrences all number
    2
    1
    Skin disorder
         subjects affected / exposed
    3 / 279 (1.08%)
    0 / 281 (0.00%)
         occurrences all number
    3
    0
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Nephrolithiasis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Endocrine disorders
    Autoimmune thyroiditis
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Hypothyroidism
         subjects affected / exposed
    3 / 279 (1.08%)
    2 / 281 (0.71%)
         occurrences all number
    3
    2
    Hyperprolactinaemia
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Musculoskeletal and connective tissue disorders
    Axillary mass
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Back pain
         subjects affected / exposed
    6 / 279 (2.15%)
    4 / 281 (1.42%)
         occurrences all number
    6
    6
    Fracture pain
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Muscle tightness
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Myalgia
         subjects affected / exposed
    2 / 279 (0.72%)
    1 / 281 (0.36%)
         occurrences all number
    2
    1
    Neck pain
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Synovitis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Infections and infestations
    Acute tonsillitis
         subjects affected / exposed
    4 / 279 (1.43%)
    6 / 281 (2.14%)
         occurrences all number
    4
    6
    Appendicitis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Borrelia infection
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Bronchitis
         subjects affected / exposed
    4 / 279 (1.43%)
    4 / 281 (1.42%)
         occurrences all number
    4
    6
    Cellulitis
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Candidiasis
         subjects affected / exposed
    2 / 279 (0.72%)
    2 / 281 (0.71%)
         occurrences all number
    2
    2
    Cervicitis
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Chlamydial infection
         subjects affected / exposed
    2 / 279 (0.72%)
    1 / 281 (0.36%)
         occurrences all number
    2
    1
    Conjunctivitis viral
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Cystitis
         subjects affected / exposed
    17 / 279 (6.09%)
    15 / 281 (5.34%)
         occurrences all number
    20
    19
    Diarrhoea infectious
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Endometritis
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Enterococcal infection
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Folliculitis
         subjects affected / exposed
    2 / 279 (0.72%)
    1 / 281 (0.36%)
         occurrences all number
    3
    1
    Gardnerella infection
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Fungal infection
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Gastroenteritis
         subjects affected / exposed
    2 / 279 (0.72%)
    4 / 281 (1.42%)
         occurrences all number
    2
    4
    Gastrointestinal viral infection
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Gonorrhoea
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Herpes zoster
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Hordeolum
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Impetigo
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Infectious mononucleosis
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    2
    Influenza
         subjects affected / exposed
    2 / 279 (0.72%)
    3 / 281 (1.07%)
         occurrences all number
    5
    3
    Kidney infection
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Laryngitis
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Mastitis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Nasopharyngitis
         subjects affected / exposed
    17 / 279 (6.09%)
    14 / 281 (4.98%)
         occurrences all number
    29
    18
    Otitis media
         subjects affected / exposed
    2 / 279 (0.72%)
    1 / 281 (0.36%)
         occurrences all number
    2
    1
    Papilloma viral infection
         subjects affected / exposed
    1 / 279 (0.36%)
    1 / 281 (0.36%)
         occurrences all number
    1
    1
    Pharyngitis
         subjects affected / exposed
    1 / 279 (0.36%)
    2 / 281 (0.71%)
         occurrences all number
    1
    2
    Pharyngitis streptococcal
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Pneumonia
         subjects affected / exposed
    0 / 279 (0.00%)
    2 / 281 (0.71%)
         occurrences all number
    0
    2
    Pulpitis dental
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Respiratory tract infection
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Pyelonephritis
         subjects affected / exposed
    2 / 279 (0.72%)
    1 / 281 (0.36%)
         occurrences all number
    3
    1
    Respiratory tract infection viral
         subjects affected / exposed
    0 / 279 (0.00%)
    2 / 281 (0.71%)
         occurrences all number
    0
    2
    Rhinitis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Salpingo-oophoritis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Salmonellosis
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Scarlet fever
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Sialoadenitis
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Sinusitis
         subjects affected / exposed
    2 / 279 (0.72%)
    6 / 281 (2.14%)
         occurrences all number
    2
    7
    Tonsillitis
         subjects affected / exposed
    3 / 279 (1.08%)
    4 / 281 (1.42%)
         occurrences all number
    3
    5
    Tooth infection
         subjects affected / exposed
    0 / 279 (0.00%)
    3 / 281 (1.07%)
         occurrences all number
    0
    3
    Urinary tract infection
         subjects affected / exposed
    11 / 279 (3.94%)
    5 / 281 (1.78%)
         occurrences all number
    11
    5
    Upper respiratory tract infection
         subjects affected / exposed
    2 / 279 (0.72%)
    1 / 281 (0.36%)
         occurrences all number
    4
    1
    Vaginal infection
         subjects affected / exposed
    8 / 279 (2.87%)
    7 / 281 (2.49%)
         occurrences all number
    11
    8
    Vaginitis bacterial
         subjects affected / exposed
    9 / 279 (3.23%)
    3 / 281 (1.07%)
         occurrences all number
    9
    3
    Vaginitis chlamydial
         subjects affected / exposed
    2 / 279 (0.72%)
    0 / 281 (0.00%)
         occurrences all number
    2
    0
    Vaginitis gardnerella
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Vulval abscess
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Vulvitis
         subjects affected / exposed
    3 / 279 (1.08%)
    0 / 281 (0.00%)
         occurrences all number
    3
    0
    Vulvovaginal candidiasis
         subjects affected / exposed
    13 / 279 (4.66%)
    7 / 281 (2.49%)
         occurrences all number
    16
    8
    Vulvovaginal mycotic infection
         subjects affected / exposed
    8 / 279 (2.87%)
    7 / 281 (2.49%)
         occurrences all number
    10
    7
    Vulvovaginitis
         subjects affected / exposed
    2 / 279 (0.72%)
    3 / 281 (1.07%)
         occurrences all number
    2
    5
    Vulvovaginitis streptococcal
         subjects affected / exposed
    3 / 279 (1.08%)
    0 / 281 (0.00%)
         occurrences all number
    3
    0
    Vulvovaginitis trichomonal
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Iron deficiency
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0
    Lactose intolerance
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Type 2 diabetes mellitus
         subjects affected / exposed
    0 / 279 (0.00%)
    1 / 281 (0.36%)
         occurrences all number
    0
    1
    Vitamin D deficiency
         subjects affected / exposed
    1 / 279 (0.36%)
    0 / 281 (0.00%)
         occurrences all number
    1
    0

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    15 Mar 2011
    The extension phase for LCS12 users was added. Several of the original exclusion criteria were clarified under Amendment 1. An 18-month Extension Phase for subjects in the LCS12 treatment group was added. The timing of Visit 2 and switching of subjects from other forms of contraception was modified. Modified the protocol in response to requests from German Health Authority, to state that in Germany, only a gynaecologist may (1) insert the LCS12 and (2) perform gynaecologic investigations and procedures required by the study protocol. The section on withdrawal of subjects from the study was modified to state that subjects experiencing new-onset of migraine with neurological symptoms, thromboembolic diseases during study treatment, icterus or pronounced increase in blood pressured MUST be withdrawn from treatment. The size of ovarian cysts to be reported as AEs from 5 cm to >3 cm was changed. Discontinued collection of dysmenorrhea data in the subjects’ diaries.
    22 Jul 2011
    The primary endpoint was clarified. Instructions regarding the use of backup contraception by LCS12 subjects who prematurely discontinued the study were modified. Safety follow-up and EOS assessments for subjects who prematurely discontinued the study was clarified. Clarified protocol to ensure that all pregnancies occurring during the study were appropriately reported to the Sponsor, not only those occurring while study drug was being used. Modified the protocol to indicate that the final clinical study report was not to include the results for the assessment of return to fertility as these data would not be available at the time of database closure. Corrected inconsistent information in the protocol regarding the time allowed between the Screening Visit and Treatment-assignment Visit. Changed definition of a compliant cycle in the COC group to indicate that no tablet could be forgotten on Cycle Days 1 through 21 and that the cycle length was to be no more than 28 days.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 01:15:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA